Advisory panel OKs Evista to reduce breast cancer risk

Share this article:

An FDA advisory panel voted to back Eli Lilly's request to tell patients its osteoporosis treatment Evista (raloxifene) also helps reduce the risk of breast cancer, despite concerns over the drug's cardiovascular side effects.

The panel of outside experts voted 10-4 in favor of allowing Lilly to re-label Evista as cutting the “risk of invasive breast cancer in women at high risk for breast cancer.”

The panel also voted 8-6 to state Evista cuts breast cancer risk “in postmenopausal women with osteoporosis.”
The votes amount to an advisory panel recommendation to approve Lilly's request to re-label and market Evista as a breast cancer reduction drug.

The FDA often follows the advice of its advisory panels, although it is not required to do so.

The panel based its recommendations on the results of four studies presented by Lilly, including results of a large National Cancer Institute Study examining Evista and an older drug tamoxifen, in relation to preventing breast cancer.

The study of nearly 20,000 postmenopausal women showed that Evista and tamoxifen cut the risk of women developing breast cancer by nearly 50%.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.